Ph-Positive Acute Lymphoblastic Leukemia
Trial of ponatinib regimen for ALL subset meets primary endpoint
The addition of ponatinib to chemotherapy increased the minimal residual disease-negative complete remission rate for certain adults with acute lymphoblastic leukemia, according to the agent’s manufacturer.
Survival rate rises steadily among patients with relapsed ALL after stem cell transplant
The 2-year OS rate nearly doubled during the past 2 decades among patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who relapsed after allogeneic hematopoietic stem cell transplantation, according to study results.
Ponatinib plus blinatumomab may provide chemotherapy-free regimen for leukemia subset
Ponatinib and blinatumomab induced high rates of complete molecular remission among patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, according to research presented during the virtual ASCO Annual Meeting.
Chemotherapy-free induction, consolidation therapy induces molecular response in Ph+ ALL
A chemotherapy-free first-line treatment strategy led to high rates of molecular response and survival among a subset of adults with acute lymphoblastic leukemia, according to study results published in The New England Journal of Medicine.